Release of silicone oil and the off-label use of syringes in ophthalmology.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
02 2020
Historique:
received: 01 01 2019
revised: 14 02 2019
accepted: 26 02 2019
pubmed: 27 3 2019
medline: 18 7 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

To assess silicone oil (SO) release by different brands of syringes used for intravitreal injection under different handling conditions. Eight syringes were analysed: from the USA, Terumo 0.5 mL, Becton-Dickinson (BD) Tuberculin 1 mL, BD Luer-lok 1 mL, BD Ultra-Fine 0.3 mL and Exel Insulin 0.3 mL; from Germany, Braun Omnifix-F 1 mL and Braun Injekt-F 1 mL and from Spain, BD Plastipak 1 mL. The impact of air, priming the plunger, agitation by flicking and fluid temperature on SO release were assessed by light microscopy. Fourier transform infrared spectroscopy (FTIR) was performed to identify the molecular compound in each syringe. Five hundred and sixty syringes were analysed. Terumo 0.5 mL and BD Ultra-Fine 0.3 mL released more SO than all others. BD Luer-lok 1 mL, BD Plastipak and Braun Omnifix-F 1 mL released little SO; BD Tuberculin 1 mL, Exel 0.3 mL and Braun Injekt-F 1 mL released the least SO. Priming the syringe and different temperatures did not significantly affect SO release. Agitation by flicking caused a significantly higher proportion of samples to have SO droplets and an increased number of oil droplets. Air had an additive effect on the release of oil in the agitation groups. FTIR identified polysiloxane in all syringes but Injekt-F. Syringes commonly used for intravitreal injections frequently release SO droplets, especially when agitated by flicking. To avoid unnecessary ocular risks, syringes should not be agitated before intravitreal injection. It is desirable that syringes be manufactured specifically for ophthalmic use.

Sections du résumé

BACKGROUND/AIMS
To assess silicone oil (SO) release by different brands of syringes used for intravitreal injection under different handling conditions.
METHODS
Eight syringes were analysed: from the USA, Terumo 0.5 mL, Becton-Dickinson (BD) Tuberculin 1 mL, BD Luer-lok 1 mL, BD Ultra-Fine 0.3 mL and Exel Insulin 0.3 mL; from Germany, Braun Omnifix-F 1 mL and Braun Injekt-F 1 mL and from Spain, BD Plastipak 1 mL. The impact of air, priming the plunger, agitation by flicking and fluid temperature on SO release were assessed by light microscopy. Fourier transform infrared spectroscopy (FTIR) was performed to identify the molecular compound in each syringe.
RESULTS
Five hundred and sixty syringes were analysed. Terumo 0.5 mL and BD Ultra-Fine 0.3 mL released more SO than all others. BD Luer-lok 1 mL, BD Plastipak and Braun Omnifix-F 1 mL released little SO; BD Tuberculin 1 mL, Exel 0.3 mL and Braun Injekt-F 1 mL released the least SO. Priming the syringe and different temperatures did not significantly affect SO release. Agitation by flicking caused a significantly higher proportion of samples to have SO droplets and an increased number of oil droplets. Air had an additive effect on the release of oil in the agitation groups. FTIR identified polysiloxane in all syringes but Injekt-F.
CONCLUSION
Syringes commonly used for intravitreal injections frequently release SO droplets, especially when agitated by flicking. To avoid unnecessary ocular risks, syringes should not be agitated before intravitreal injection. It is desirable that syringes be manufactured specifically for ophthalmic use.

Identifiants

pubmed: 30910872
pii: bjophthalmol-2019-313823
doi: 10.1136/bjophthalmol-2019-313823
doi:

Substances chimiques

Silicone Oils 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-296

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Gustavo Barreto Melo (GB)

Hospital de Olhos de Sergipe, Aracaju, Brazil gustavobmelo@yahoo.com.br.
Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.

Geoffrey Guy Emerson (GG)

Retina Center of Minnesota, Minneapolis, Minnesota, USA.

Celso Souza Dias (CS)

Hospital de Olhos de Sergipe, Aracaju, Brazil.

Fábio Barreto Morais (FB)

Hospital de Olhos de Sergipe, Aracaju, Brazil.
Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.

Acacio de Souza Lima Filho (AS)

Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Vision Institute, IPEPO, São Paulo, Brazil.

Shoko Ota (S)

Chemical Analysis Laboratory, Center for Chemistry and Manufactured Goods, Institute for Technological Research, São Paulo, Brazil.

Michel Eid Farah (ME)

Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Vision Institute, IPEPO, São Paulo, Brazil.

Eduardo Büchele Rodrigues (EB)

Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Vision Institute, IPEPO, São Paulo, Brazil.

Maurício Maia (M)

Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Vision Institute, IPEPO, São Paulo, Brazil.

Rubens Belfort (R)

Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
Vision Institute, IPEPO, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH